A Study to Evaluate Response to Adalimumab in Rheumatoid Arthritis Patients


About this study

The purpose of this study is to collect clinical and biological measures to develop an Artificial Intelligence based algorithm and clinical decision support tool to predict the 12-week response to adalimumab, a tumor necrosis factor receptor antagonist in adults with a clinical diagnosis of rheumatoid arthritis. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Outpatients with rheumatoid arthritis defined by American College of Rheumatology 2010 criteria.
  • Patients whose biologic therapy with Humira has been prescribed by their physician[AAM1]  as standard of care, after failure or incomplete control of disease with at least 3 months therapy with methotrexate or other oral immunomodulators[AAM2].
  • Adults between 18-80 years of age.
  • Ability to provide informed consent.
  • Ability to understand English either personally or through a translator.

Exclusion Criteria:

  • Outpatients with rheumatoid arthritis who have not been prescribed Humira by their physician as standard of care.
  • Patients younger than 18 years of age or older than 80 years of age.
  • Patient’s unable to provide informed consent.
  • Patients unable to understand English either personally or through a translator.
  • Patients who are pregnant or breast-feeding.
  • Patients with rheumatoid arthritis who are stable on current therapy with Humira, as prescribed by their physician as standard of care.
  • Patient has already begun taking Humira prescribed by physician as standard of care before screening/baseline visit.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Andy Abril, M.D.

Closed-enrolling by invitation

What is this? (?)
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Quantia Wilkes M.S.

(904) 953-3636


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer